Encysive says Barr files ANDA for generic version of Argatroban
Nov 23 (Reuters) - Encysive Pharmaceuticals Inc ENCY.O said it received a notice that Barr Laboratories Inc (BRL.N: Quote, Profile, Research, Stock Buzz) had filed an abbreviated new drug application for a generic version of its drug, Argatroban, to treat heparin-induced thrombocytopenia.
Heparin-induced thrombocytopenia refers to the decrease in blood platelet count following the administration of heparin, which is an anticoagulant.
Encysive said it had 45 days to start a patent infringement lawsuit against Barr that would automatically stay, or bar, the U.S. Food and Drug Administration from approving Barr's ANDA for 30 months, or until a district court decision against Encysive.
The patent expires in June 2014, the company said in a filing. (Reporting by Sayantani Ghosh in Bangalore; Editing by Pratish Narayanan)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Tighter race?
Asia greets G7 weekend pledges